Journal of Hepatology
Volume 50, Issue 3 , Pages 592-603 , March 2009

Alteration of protein glycosylation in liver diseases

  • Bram Blomme

      Affiliations

    • Department of Hepatology and Gastroenterology, Ghent University Hospital, B-9000 Ghent, Belgium
    • ,
  • Christophe Van Steenkiste

      Affiliations

    • Department of Hepatology and Gastroenterology, Ghent University Hospital, B-9000 Ghent, Belgium
    • ,
  • Nico Callewaert

      Affiliations

    • Unit for Molecular Glycobiology, Department for Molecular Biomedical Research, VIB, Ghent University, Ghent, Belgium
    • Department of Biochemistry, Physiology and Microbiology, Ghent University, Ghent, Belgium
    • ,
  • Hans Van Vlierberghe

      Affiliations

    • Department of Hepatology and Gastroenterology, Ghent University Hospital, B-9000 Ghent, Belgium
    • Corresponding Author InformationCorresponding author.

References 

  1. Ploegh H, Neefjes JJ. Protein glycosylation. Curr Opin Cell Biol. 1990;2:1125–1130
  2. Hebert DN, Garman SC, Molinari M. The glycan code of the endoplasmic reticulum: asparagine-linked carbohydrate as protein maturation and quality-control tags. Trends in Cell Biol. 2005;15:364–370
  3. Kornfeld S. Diseases of abnormal protein glycosylation: an emerging area. J Clin Invest. 1998;101:1293–1295
  4. Lis H, Sharon N. Protein glycosylation: structural and functional aspects. Eur J Biochem. 1993;218:1–27
  5. Schachter H. The subcellular sites of glycosylation. Biochem Soc Symp. 1974;40:57–71
  6. Paulson JC, Colley KJ. Glycosyltransferases – structure, localization, and control of cell type-specific glycosylation. J Biol Chem. 1989;264:17615–17618
  7. Spiro RG. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptides bonds. Glycobiology. 2002;12:43R–56R
  8. Burda P, Aebi M. The dolichol pathway of N-linked glycosylation. Biochem Biophys Acta. 1999;1426:239–257
  9. Javaud C, Dupuy F, Maftah A, Julien R, Petit JM. The fucosyltransferase gene family: an amazing summary of the underlying mechanisms of gene evolution. Genetica. 2003;118:157–170
  10. Taniguchi N, Miyoshi E, Ko JH, Ikeda Y, Ihara Y. Implication of N-acetylglucosaminyltransferases III and V in cancer: gene regulation and signaling mechanism. Biochim Biophys Acta. 1999;1455:287–300
  11. Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P. The human sialyltransferase family. Biochimie. 2001;83:727–737
  12. Zhao Y, Takahashi M, Gu J, Miyoshi E, Matsumoto A, Kitazume S, et al. Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer Sci. 2008;99:1304–1310
  13. Varki A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology. 1993;3:97–130
  14. Dwek RA. Glycobiology: ‘towards understanding the function of sugars’. Biochem Soc Trans. 1995;23:1–25
  15. Taniguchi N, Miyoshi E, Gu J, Honke K, Matsumoto A. Decoding sugar functions by identifying target glycoproteins. Curr Opin Struct Biol. 2006;16:561–566
  16. Sawamura T, Nakada H, Hazama H, Shiozaki Y, Sameshima Y, Tashiro Y. Hyperasialoglycoproteinemia in patients with chronic liver-diseases and or liver-cell carcinoma – asialoglycoprotein receptor in cirrhosis and liver-cell carcinoma. Gastroenterology. 1984;87:1217–1221
  17. Burgess JB, Baenziger JU, Brown WR. Abnormal surface distribution of the human asialoglycoprotein receptor in cirrhosis. Hepatology. 1992;15:702–706
  18. Martinez J, Barsigian C. Carbohydrate abnormalities of N-linked plasma glycoproteins in liver-disease. Lab Invest. 1987;57:240–257
  19. Turner GA. N-glycosylation of serum–proteins in disease and its investigation using lectins. Clin Chim Acta. 1992;208:149–171
  20. Van Damme EJM, Peumans WJ, Bardocz S, Pusztai A. Handbook of plant lectins: properties and biomedical applications. Amsterdam: John Wiley & Sons; 1998;
  21. De Jong G, Van Dijk JP, Van Eijk HG. The biology of transferrin. Clin Chim Acta. 1990;190:1–46
  22. Flahaut C, Michalski JC, Danel T, Humbert MH, Klein A. The effects of ethanol on the glycosylation of human transferrin. Glycobiology. 2003;13:191–198
  23. Storey EL, Anderson GJ, Mack U, Powell LW, Halliday JW. Desialylated transferrin as a serological marker of chronic excessive alcohol ingestion. Lancet. 1987;1:1292–1294
  24. Cottalasso D, Domenicotti C, Traverso N, Pronzato MA, Nanni G. Influence of chronic ethanol consumption on toxic effects of 1,2-dichloroethane: glycolipoprotein retention and impairment of dolichol concentration in rat liver microsomes and Golgi apparatus. Toxicology. 2002;178:229–240
  25. Rao M, Lakshman MR. Chronic ethanol consumption leads to destabilization of rat liver β-galactoside-sialyltransferase mRNA. Metabolism. 1999;48:797–803
  26. Xin Y, Lasker JM, Lieber CS. Serum carbohydrate-deficient transferrin – mechanism of increase after chronic alcohol intake. Hepatology. 1995;22:1462–1468
  27. Gong M, Garige M, Hirsch K, Lakshman MR. Liver Gal beta 1,4GlcNAc alpha 2,6-sialyltransferase is down-regulated in human alcoholics: possible cause for the appearance of asialoconjugates. Metabolism. 2007;56:1241–1247
  28. Liu YS, Xu GY, Cheng DQ, Li YM. Determination of serum carbohydrate-deficient transferrin in the diagnosis of alcoholic liver disease. Hepatobiliary Pancreat Dis Int. 2005;4:265–268
  29. Stadheim LM, O’Brien JF, Lindor KD, Gores GJ, McGill DB. Value of determining carbohydrate-deficient transferrin isoforms in the diagnosis of alcoholic liver disease. Mayo Clin Proc. 2003;78:703–707
  30. Tsutsumi M, Wang JS, Takada A. Microheterogeneity of serum glycoproteins in alcoholics – is desialo-transferrin the marker of chronic alcohol-drinking or alcoholic liver-injury. Alcohol Clin Exp Res. 1994;18:392–397
  31. Chrostek L, Cylwik B, Korcz W, Krawiec A, Koput A, Supronowicz Z, et al. Serum free sialic acid as a marker of alcohol abuse. Alcohol Clin Exp Res. 2007;31:996–1001
  32. Mann AC, Record CO, Self CH, Turner GA. Monosaccharide composition of haptoglobin in liver-diseases and alcohol-abuse – large changes in glycosylation associated with alcoholic liver-disease. Clin Chim Acta. 1994;227:69–78
  33. Chambers W, Thompson S, Skillen AW, Record CO, Turner GA. Abnormally fucosylated haptoglobin as a marker for alcoholic liver-disease but not excessive alcohol-consumption or Nonalcoholic liver-disease. Clin Chim Acta. 1993;219:177–182
  34. Jezequel M, Seta NS, Corbic MM, Feger JM, Durand GM. Modifications of concanavalin a patterns of alpha-1-acid glycoprotein and alpha-2-Hs glycoprotein in alcoholic liver-disease. Clin Chim Acta. 1988;176:49–57
  35. Matsuda Y, Takada A, Takase S, Sato H. Accumulation of glycoprotein in the Golgi-apparatus of hepatocytes in alcoholic liver injuries. Am J Gastroenterol. 1991;86:854–860
  36. Guasch R, Renaupiqueras J, Guerri C. Chronic ethanol-consumption induces accumulation of proteins in the liver Golgi-apparatus and decreases galactosyltransferase activity. Alcohol Clin Exp Res. 1992;16:942–948
  37. Ghosh P, Liu QH, Lakshman MR. Long-term ethanol exposure impairs glycosylation of both N- and O-glycosylated proteins in rat-liver. Metabolism. 1995;44:890–898
  38. Ihara Y, Yoshimura M, Miyoshi E, Nishikawa A, Sultan AS, Toyosawa S, et al. Ectopic expression of N-acetylglucosaminyltransferase III in transgenic hepatocytes disrupts apolipoprotein B secretion and induces aberrant cellular morphology with lipid storage. Proc Natl Acad Sci USA. 1998;95:2526–2530
  39. Lee J, Song EY, Chung TW, Kang SK, Kim KS, Chung TH, et al. Hyperexpression of N-acetylglucosaminyltransferase-III in liver tissues of transgenic mice causes fatty body and obesity through severe accumulation of Apo A-I and Apo B. Arch Biochem Biophys. 2004;426:18–31
  40. Wang W, Li W, Ikeda Y, Miyagawa JI, Taniguchi M, Miyoshi E, et al. Ectopic expression of alpha1,6 fucosyltransferase in mice causes steatosis in the liver and kidney accompanied by a modification of lysosomal acid lipase. Glycobiology. 2001;11:165–174
  41. Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem. 2006;281:29797–29806
  42. Miyoshi E, Nishikawa A, Ihara Y, Hayashi N, Fusamoto H, Kamada T, et al. Selective suppression of N-acetylglucosaminyltransferase-Iii activity in a human hepatoblastoma cell-line transfected with hepatitis-B virus. Cancer Res. 1994;54:1854–1858
  43. Miyoshi E, Ihara Y, Hayashi N, Fusamoto H, Kamada T, Taniguchi N. Transfection of N-acetylglucosaminyltransferase-Iii gene suppresses expression of hepatitis-B virus in a human hepatoma-cell line, Hb611. J Biol Chem. 1995;270:28311–28315
  44. Shim JK, Lee YC, Chung TH, Kim CH. Elevated expression of bisecting N-acetylglucosaminyltransferase-III gene in a human fetal hepatocyte cell line by hepatitis B virus. J Gastroenterol Hepatol. 2004;19:1374–1387
  45. Kang SK, Chung TW, Lee JY, Lee YC, Morton RE, Kim CH. The hepatitis B virus x protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III. J Biol Chem. 2004;279:28106–28112
  46. Anderson N, Pollacchi A, Hayes P, Therapondos G, Newsome P, Boyter A, et al. A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases. Biomed Chromatogr. 2002;16:365–372
  47. Cao Y, Merling A, Crocker PR, Keller R, Schwartz-Albiez R. Differential expression of beta-galactoside alpha 2,6 sialyltransferase and sialoglycans in normal and cirrhotic liver and hepatocellular carcinoma. Lab Invest. 2002;82:1515–1524
  48. Dall’Olio F, Chiricolo M, D’Errico A, Gruppioni E, Altimari A, Fiorentino M, et al. Expression of beta-galactoside alpha 2,6 sialyltransferase and of alpha 2,6-sialylated glycoconjugates in normal human liver, hepatocarcinoma, and cirrhosis. Glycobiology. 2004;14:39–49
  49. Pousset D, Piller V, Bureaud N, Monsigny M, Piller F. Increased alpha 2,6 sialylation of N-glycans in a transgenic mouse model of hepatocellular carcinoma. Cancer Res. 1997;57:4249–4256
  50. Bayard B, Kerckaert JP. Characterization and isolation of nine rat alpha-fetoprotein variants by gel electrophoresis and lectin affinity chromatography. Biochem Biophys Res Commun. 1977;77:489–495
  51. Karvountzis GG, Redeker AG. Relation of alpha-fetoprotein in acute hepatitis to severity and prognosis. Ann Intern Med. 1974;80:156–160
  52. Aoyagi Y, Suzuki Y, Isemura M, Nomoto M, Sekine C, Igarashi K, et al. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular-carcinoma. Cancer. 1988;61:769–774
  53. Aoyagi Y, Saitoh A, Suzuki Y, Igarashi K, Oguro M, Yokota T, et al. Fucosylation index of alpha-fetoprotein, a possible aid in the early recognition of hepatocellular-carcinoma in patients with cirrhosis. Hepatology. 1993;17:50–52
  54. Du MQ, Hutchinson WL, Johnson PJ, Williams R. Differential alpha-fetoprotein lectin binding in hepatocellular-carcinoma – diagnostic utility at low serum levels. Cancer. 1991;67:476–480
  55. Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohta Y, Endo Y, et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular-carcinoma and related conditions. Gastroenterology. 1990;99:508–518
  56. Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol. 2007;102:2196–2205
  57. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001;313:15–19
  58. Yamashiki N, Seki T, Wakabayashi M, Nakagawa T, Imamura M, Tamai T, et al. Usefulness of lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein (AFP-L3) as a marker of distant metastasis from hepatocellular carcinoma. Oncol Rep. 1999;6:1229–1232
  59. Noda K, Miyoshi E, Uozumi N, Yanagidani S, Ikeda Y, Gao CX, et al. Gene expression of alpha 1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of alpha-fetoprotein. Hepatology. 1998;28:944–952
  60. Aoyagi Y, Suzuki Y, Igarashi K, Saitoh A, Oguro M, Yokota T, et al. Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans. Br J Cancer. 1993;67:486–492
  61. Campion B, Leger D, Wieruszeski JM, Montreuil J, Spik G. Presence of fucosylated triantennary, tetraantennary and pentaantennary glycans in transferrin synthesized by the human hepatocarcinoma cell line Hep G2. Eur J Biochem. 1989;184:405–413
  62. Ohno M, Nishikawa A, Koketsu M, Taga H, Endo Y, Hada T, et al. Enzymatic basis of sugar structures of alpha-fetoprotein in hepatoma and hepatoblastoma cell lines: correlation with activities of alpha 1-6 fucosyltransferase and N-acetylglucosaminyltransferases III and V. Int J Cancer. 1992;51:315–317
  63. Sekine C, Aoyagi Y, Suzuki Y, Ichida F. The reactivity of alpha-1-antitrypsin with lens-culinaris agglutinin and its usefulness in the diagnosis of neoplastic diseases of the liver. Br J Cancer. 1987;56:371–375
  64. Saitoh A, Aoyagi Y, Asakura H. Structural analysis on the sugar chains of human alpha 1-antitrypsin: presence of fucosylated biantennary glycan in hepatocellular carcinoma. Arch Biochem Biophys. 1993;303:281–287
  65. Hodges LC, Laine R, Chan SK. Structure of the oligosaccharide chains in human alpha-1-protease inhibitor. J Biol Chem. 1979;254:8208–8212
  66. Yamashita K, Koide N, Endo T, Iwaki Y, Kobata A. Altered glycosylation of serum transferrin of patients with hepatocellular-carcinoma. J Biol Chem. 1989;264:2415–2423
  67. Matsumoto K, Maeda Y, Kato S, Yuki H. Alteration of asparagine-linked glycosylation in serum transferrin of patients with hepatocellular-carcinoma. Clin Chim Acta. 1994;224:1–8
  68. Suzuki Y, Aoyagi Y, Mori S, Suda T, Naitoh A, Isokawa O, et al. Microheterogeneity of serum transferrin in the diagnosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 1996;11:358–365
  69. Kudo T, Nakagawa H, Takahashi M, Hamaguchi J, Kamiyama N, Yokoo H, et al. N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma. Mol Cancer. 2007;6:32
  70. Narasimhan S, Schachter H, Rajalakshmi S. Expression of N-acetylglucosaminyltransferase-Iii in hepatic Nodules during rat-liver carcinogenesis promoted by orotic-acid. J Biol Chem. 1988;263:1273–1281
  71. Mori S, Aoyagi Y, Yanagi M, Suzuki Y, Asakura H. Serum N-acetylglucosaminyltransferase III activities in hepatocellular carcinoma. J Gastroenterol Hepatol. 1998;13:610–619
  72. Song EY, Kang SK, Lee YC, Park YG, Chung TH, Kwon DH, et al. Expression of bisecting N-acetylglucosaminyltransferase-III in human hepatocarcinoma tissues, fetal liver tissues, and hepatoma cell lines of Hep3B and HepG2. Cancer Invest. 2001;19:799–807
  73. Bhaumik M, Harris T, Sundaram S, Johnson L, Guttenplan J, Rogler C, et al. Progression of hepatic neoplasms is severely retarded in mice lacking the, bisecting N-acetylglucosamine on N-glycans: evidence for a glycoprotein factor that facilitates hepatic tumor progression. Cancer Res. 1998;58:2881–2887
  74. Yang XP, Bhaumik M, Bhattacharyya R, Gong S, Rogler CE, Stanley P. New evidence for an extra-hepatic role of N-acetylglucosaminyltransferase III in the progression of diethylnitrosamine-induced liver tumors in mice. Cancer Res. 2000;60:3313–3319
  75. Yang XP, Tang J, Rogler CE, Stanley P. Reduced hepatocyte proliferation is the basis of retarded liver tumor progression and liver regeneration in mice lacking N-acetylglucosaminyltransferase III. Cancer Res. 2003;63:7753–7759
  76. Dennis JW, Laferte S, Waghorne C, Breitman ML, Kerbel RS. Beta-1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science. 1987;236582–236585
  77. Yanagi M, Aoyagi Y, Suda T, Mita Y, Asakura H. N-acetylglucosaminyltransferase V as a possible aid for the evaluation of tumor invasiveness in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16:1282–1289
  78. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta. 1999;1473:21–34
  79. Miyoshi E, Nishikawa A, Ihara Y, Gu JG, Sugiyama T, Hayashi N, et al. N-acetylglucosaminyltransferase-Iii and N-acetylglucosaminyltransferase-V messenger-RNA levels in Lec rats during hepatocarcinogenesis. Cancer Res. 1993;53:3899–3902
  80. Nishikawa A, Gu J, Fujii S, Taniguchi N. Determination of N-acetylglucosaminyltransferase-Iii, N-acetylglucosaminyltransferase-Iv and N-acetylglucosaminyltransferase-V in normal and hepatoma tissues of rats. Biochim Biophys Acta. 1990;1035:313–318
  81. Koenderman AH, Koppen PL, Koeleman CA, van den Eijnden DH. N-acetylglucosaminyltransferase III, IV and V activities in Novikoff ascites tumour cells, mouse lymphoma cells and hen oviduct. Application of a sensitive and specific assay by use of high-performance liquid chromatography. Eur J Biochem. 1989;181:651–655
  82. Guo HB, Jiang AL, Ju TZ, Chen HL. Opposing changes in N-acetylglucosaminyltransferase-V and -III during the cell cycle and all-trans retinoic acid treatment of hepatocarcinoma cell line. Biochim Biophys Acta. 2000;1495:297–307
  83. Yao M, Zhou DP, Jiang SM, Wang QH, Zhou XD, Tang ZY, et al. Elevated activity of N-acetylglucosaminyltransferase V in human hepatocellular carcinoma. J Cancer Res Clin Oncol. 1998;124:27–30
  84. Ito Y, Miyoshi E, Sakon M, Takeda T, Noda K, Tsujimoto M, et al. Elevated expression of UDP-N-acetylglucosamine: alphamannoside beta1,6 N-acetylglucosaminyltransferase is an early event in hepatocarcinogenesis. Int J Cancer. 2001;91:631–637
  85. Bosques CJ, Raguram S, Sasisekharan R. The sweet side of biomarker discovery. Nat Biotechnol. 2006;24:1100–1101
  86. Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R. Glycomics: an integrated systems approach to structure-function relationships of glycans. Nat Methods. 2005;2:817–824
  87. Gravel P, Walzer C, Aubry C, Balant LP, Yersin B, Hochstrasser DF, et al. New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution two-dimensional gel electrophoresis. Biochem Biophys Res Commun. 1996;220:78–85
  88. Henry H, Froehlich F, Perret R, Tissot JD, Eilers-Messerli B, Lavanchy D, et al. Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. Clin Chem. 1999;45:1408–1413
  89. Laroy W, Contreras R, Callewaert N. Glycome mapping on DNA sequencing equipment. Nat Protoc. 2006;1:397–405
  90. Turnbull JE, Field RA. Emerging glycomics technologies. Nat Chem Biol. 2007;3:74–77
  91. Miyamoto S. Clinical applications of glycomic approaches for the detection of cancer and other diseases. Curr Opin Mol Ther. 2006;8:507–513
  92. Morelle W, Michalski JC. Glycomics and mass spectrometry. Curr Pharm Des. 2005;11:2615–2645
  93. Pilobello KT, Mahal LK. Deciphering the glycocode: the complexity and analytical challenge of glycomics. Curr Opin Chem Biol. 2007;11:300–305
  94. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med. 2004;10:429–434
  95. Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 2007;46:1426–1435
  96. Kam RKT, Poon TCW, Chan HLY, Wong N, Hui AY, Sung JJY. High-throughput quantitative profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic fingerprint of liver fibrosis. Clin Chem. 2007;53:1254–1263
  97. Morelle W, Flahaut C, Michalski JC, Louvet A, Mathurin P, Klein A. Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. Glycobiology. 2006;16:281–293
  98. Stahl B, Thurl S, Zeng JR, Karas M, Hillenkamp F, Steup M, et al. from human milk as revealed by matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem. 1994;223:218–226
  99. Harvey DJ. Quantitative aspects of the matrix-assisted laser-desorption mass-spectrometry of complex oligosaccharides. Rapid Commun Mass Spectrom. 1993;7:614–619
  100. Mehta AS, Long RE, Comunale MA, Wang M, Rodemich L, Krakover J, et al. Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol. 2008;82:1259–1270

☆ The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(08)00802-7

doi: 10.1016/j.jhep.2008.12.010

Journal of Hepatology
Volume 50, Issue 3 , Pages 592-603 , March 2009

Article Tools

* Image Usage & Resolution